PTEN, also known as Phosphatidylinositol-3 and 4, 5-Trisphosphate 3-phosphatase, and dual-specificity protein phosphatase, is a tumor suppressor and is also a member of the PI3K/PTEN/Akt pathways. Defects of this antibody have been implicated in human cancers of the breast, thyroid, prostate, endometrium, skin, brain, neck, and head. Up to 60 percent of all advanced prostate cancers show an abnormal PTEN gene expression or a complete loss of protein expression.
The PTEN antibody has a clone of SP218, and the immunogen is the synthetic peptide that is derived from the C-terminus of the protein with the same name. The isotype is the Rabbit IgG, and it has an undetermined epitope with a molecular weight of 54 kDa.
It can be used in a variety of applications, including Flow Cytometry, Western Blotting, and Immunohistochemistry.
For Flow Cytometry applications, the positive control is the A431 Cell Line with cellular localization happening in the nucleus or cytoplasm.
For Western Blotting, the recommended protocol is to dilute the antibody using a ratio of 1:200. Incubate the concoction for 30 minutes at four degrees Celsius. The positive control will be the HeLa Cell Lysate.
For IHC applications, you should use paraffin-embedded or Formalin-fixed tissues. You should dilute the antibody using a ratio of 1:200 and you can also find a pre-diluted formula available. To retrieve the antigen, you should boil the tissue sections for ten minutes in a Citrate buffer with a pH of 6.0. Then, allow it to cool for 20 minutes. Incubation periods are 30 minutes while at room temperature. The positive control is the prostate or prostate Adenocarcinoma with cellular localization also occurring in the cytoplasm or nucleus.
The PTEN antibody can be used to help research a variety of cancers. Visit Spring Bioscience today for more information.